Abstract. The aim of the study was to determine whether the controlled release of interleukin (IL)-1Ra from chitosan (CS) microspheres inhibits the IL-1β-stimulated production of matrix metalloproteinases (MMPs) in chondrocytes. The CS‐IL‐1Ra microspheres were fabricated by an emulsifica- tion metho
PANG-HU ZHOU,MA BEI-LEI,LEI SHI,TING XIE,BO QIU
2014-01-01
Abstract:The aim of the study was to determine whether the controlled release of interleukin (IL)-1Ra from chitosan (CS) microspheres inhibits the IL-1β-stimulated production of matrix metalloproteinases (MMPs) in chondrocytes. The CS‐IL‐1Ra microspheres were fabricated by an emulsification method using sodium tripolyphosphate as a crosslinker, and the controlled release of IL-1Ra was determined using an enzyme-linked immunosorbent assay. IL-1β was added to normal rat chondrocytes to stimulate MMP production. The chondrocytes were incubated with CS-IL-1Ra microspheres to assess its effects on IL-1β-induced MMP expression. Chondrocyte proliferation and glycosaminoglycan (GAG) content were also determined. The mRNA expression and protein levels of IL-1β, MMP-1, MMP-3 and MMP-13 were detected using reverse transcription-polymerase chain reaction and western blotting analyses, respectively. The IL-1Ra release kinetics were characterized by an initial burst release, which was reduced to a linear release over seven days. The mRNA expression levels and protein levels of IL-1β, MMP-1, MMP-3 and MMP-13 were reduced compared with the control group. The present study demonstrated the chondroprotective properties of CS microspheres as a controlled release system carrying IL-1Ra, due to the ability of the system to downregulate the expression of osteoarthritis-associated matrix-degrading proteinases in chondrocytes. Introduction Osteoarthritis (OA) is an age-related degenerative joint disease that at its late stage is characterized by extensive cartilage destruction and the loss of chondrocytes. The loss of the major components of the extracellular matrix (ECM) as a result of increased synthesis of matrix metalloproteases (MMPs) and aggrecanases (such as, ADAMTS), as well as reduced glycosaminoglycan (GAG) synthesis, has been well-documented during OA progression (1,2). MMPs are zinc-containing, calcium-dependent proteinases, which collectively degrade all components of the extracellular matrix and have a critical role in intrinsic chondrocyte-mediated degenerative changes in the cartilage matrix in OA (3). MMPs are often expressed in chondrocytes in response to major inflammatory cytokines, including interleukin (IL)-1β, which is produced by the synovium and other joint tissues (4). IL-1β has been thoroughly investigated, particularly its role as a key mediator of cartilage destruction in OA due to its ability to induce or upregulate the expression of proteinases, including MMPs, plasminogen activators and aggrecanases, and to downregulate the expression of endogenous proteinase inhibitors (for example, specific tissue inhibitors of metalloproteinases) (5-7). These products disrupt the metabolic balance of chondrocytes, resulting in a perturbation of the chondrocyte phenotype by reducing type II collagen expression (5,6). This process induces specific degradation, and consequently the inhibition of the IL-1β pathway presents a promising means to prevent cartilage degradation during OA pathogenesis. One of the major endogenous inhibitors of the IL-1 pathway is the IL-1 receptor antagonist (IL‐1Ra). IL‐1Ra is a well‐known anti‐inflammatory cytokine that is a member of the IL-1 family. IL-1Ra binds to the IL-1RI receptor with similar specificity and affinity but does not activate downstream signals (8,9). In addition, IL-1Ra has been used as a gene therapeutic strategy in the treatment of OA, suggesting that it may also be appropriate for the treatment of early-stage, cytokine-mediated cartilage degeneration (10,11). With the aim of enhancing the potential role of IL-Ra in the treatment of OA, it was proposed that the encapsulation of this macromolecule in select microspheres capable of positively Inhibition of interleukin‐1β‐stimulated matrix metalloproteinases via the controlled release of interleukin‐1Ra from chitosan microspheres in chondrocytes PANG-HU ZHOU1*, BEI-LEI MA2*, LEI SHI3, TING XIE4 and BO QIU1 1Department of Orthopedics, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060; 2Department of Laboratory, Qilu Hospital of Shandong University, Jinan, Shandong 250012; 3Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060; 4Department of Women Health Care, Hubei Women and Children's Hospital, Wuhan, Hubei 430070, P.R. China Received December 19, 2013; Accepted July 21, 2014 DOI: 10.3892/mmr.2014.2743 Correspondence to: Dr Pang-Hu Zhou, Department of Orthopedics, Renmin Hospital of Wuhan University, 99 Ziyang Road, Wuhan, Hubei 430060, P.R. China E-mail: zhoupanghu@gmail.com; zhoupanghu@126.com *Contributed equally